Special dermatitis market competition expanded, two major therapies have been approved in China, a number of JAK inhibitors ready to develop!

Guide: Two Major AD therapies have been approved in China! On July 30, the National Drug Administration's official website showed that Pfizer's new drug, Atopic dermatitis (AD), was approved for use in patients with mild to severe AD patients 2 years and older.
two AD therapies have been approved in China as a nonsteroidal PDE4 inhibitor, PDE4 mediated adenosine cyclophosphate (cAMP) to the conversion of adenosine monophosphate (AMP), thereby reducing the level of AMPc in the cell.
the drug was originally developed by The American biopharmaceutical company Anacor, which Pfizer acquired in December 2016 for $5.2 billion in cash, and Eucrisa, the central asset of the deal, was bought by Pfizer.
In the United States, Eucrisa was approved for use in children and adults 2 years of age and older with mild to moderate AD patients on December 14, 2016, making Eucrisa the first new molecular entity approved by the U.S. FDA for a treatment of AD in the past 15 years.
In March, the FDA approved Eucrisa's application for a new drug that allows it to be used in patients with mild to moderate AD in three-to-24-month-old children, making Eucrisa the first hormone-free local prescription drug for children with mild to moderate AD over 3 months of age.
in China, Eucrisa uses the disease as a chronic recurrent inflammatory skin disease with limited treatment methods that provide an effective drug option for patients who are not tolerated or ineffective in existing therapies.
" was included in the second batch of clinically urgently needed new drugs. On February 10,
, Pfizer's application for a listing in China for The Crepoo ointment was accepted by CDE.
more than a month before Eucrisa, Sanofi/Regenerative's heavyweight AD treatment Dupixent was approved for sale in China.
Dupixent is an all-human monoclonal antibody that specifically inhibits the overactivation of two key proteins, IL-4 and IL-13.
IL-4/IL-13 are two inflammatory factors and are considered to be key drivers of persistent internal inflammation of AD.
March 2017, Dupixent obtained FDA approval for use in adult patients with moderate to severe optoderitis that do not adequately control the condition or are not suitable for these medications, becoming the first targeted biological drug to be used to treat moderate to severe adhesion it in adults.
, Dupixent has been approved for three indications, in addition to AD, as well as moderate to severe asthma (s.12 years), chronic nasal sinusitis (adults) with nasal polyps.
as early as July 2018, EvaluatePharma took stock of AD innovative therapies that are already available and coming to market in the next few years, and forecast sales of these innovative therapies in 2024, with Dupixent topping the list with $5.1 billion and Eucrisa in second place.
now, these two treatments have been approved in China, and we expect them to benefit more AD patients in China as soon as possible.
JAK inhibitor "New Battlefield" AD is a special type of eczema, a serious chronic inflammatory skin disease, mainly characterized by severe itching, significant eczema-like change and dry skin.
in the United States, AD affects nearly 18 million adults and about 11 percent of children.
, about 10% of adults and 20% of children worldwide are affected by adhesion altrate, of which 45% occur six months ago, 60% before the age of one, 85% before the age of 5, and about 50% of children experience recurrent episodes in adolescence and adulthood. as a result, there is a significant unmet medical need for innovative therapies in this area,
.
a number of JAK inhibitors have achieved positive results in a number of Phase 3 clinical trials against AD this year, and the AD field has become another competition for JAK inhibitors.
listed/clinically phase 3-used in AD JAK inhibitor upadacitinib Rinvoq (upadacitinib) was discovered and developed by AbbVie family and is an oral, daily, selective and reversible JAK inhibitor.
August 2019, the drug was approved by the U.S. FDA for use in adult patients with moderate to severe active rheumatoid arthritis who are under-responsive or intolerant.
has been reported so far this year and has achieved positive results in three key phase 3 studies of adacitinib. On July 28,
, AbbVie announced that upadacitinib had been used in conjunction with external corticosteroids (TCS) to achieve a common primary and all secondary endpoint in the critical Phase 3 clinical trial AD Up.
at 16 weeks, more patients in the group who received any dose of upacitinib-TCS achieved significant improvements in skin symptoms compared to placebo s.TCS.
AD Up trial results On July 21, AbbVie announced that The Second Phase 3 Clinical Trial of Rinvoq Single Drug Treatment for Severe AD, Measure Up 2, had reached the primary and all secondary endpoints.
compared to placebo, upadacitinib showed significant improvement in skin removal and reduced itching at week 16.
Measure Up 2 trial results June 19, upadacitinib as a key phase 3 clinical trial for the treatment of moderate aD patients in the treatment of single-drug therapy, the results of the measure up 1 results, the study reached a common primary endpoint, significantly reducing the skin symptoms of patients.
Measure Up 1 trial result abrocitinib Abrocitinib (PF-04965842) is an oral small molecule highly selective JAK1 inhibitor developed by Pfizer.
February 2018, the drug was granted the FDA's breakthrough drug qualification for the treatment of moderate and severe AD.
this year, abrocitinib has been treating AD with good news.
early June, Pfizer announced the full results of the second critical single drug Phase III study (JADE MONO-2) for abrocitinib therapy AD.
the study was conducted in patients aged 12 and over with moderate to severe AD, and the data were consistent with the first single drug Phase III study (JADE MONO-1): the study reached all common primary and critical secondary endpoints.
both doses of abrocitinib showed statistical lysin advantages in improving skin loss removal, eczema area and severity, and itching compared to placebo.
the efficacy of the JADE MONO-2 study, pfizer also published the results of two other trials of JADE COMPARE and JADE TEEN in its Jade-BASED dermatitis efficacy and safety development program (JADE).
results show that both studies also reached the main clinical endpoint.
additional data from other studies from the JADE project will be available later this year.
baricitinib Olumib, developed by Incyte, in 2009 Lilly reached an exclusive partnership with Incyte on baricitinib and some subsequent compounds.
the drug has been approved by the U.S. FDA for treatment of patients with moderate to severe active rheumatoid arthritis who do not respond adequately to TNF inhibitor therapy.
August 2019, Lilly and Incyte jointly announced that baricitinib was combined with external corticosteroids to reach the primary endpoint in stage 3 clinical trial breeze-AD7 in patients with moderate aD, and that at week 16 of treatment, the baricitinib group reached a significantly higher proportion of patients with skin symptom removal or almost removal (vAIG,1) than in the placebo group.
Breeze-AD7 trial results Lilly and Incyte have high hopes for baricitinib treatment AD, conducting seven Phase III trials (Breeze-AD1-7) in one breath, with only 52 weeks of single-drug treatment remaining.
With the release of a number of positive data from abrocitinib and upadacitinib, baricitinib's previous apparent advantage appears to be narrowing.
in addition to the above three oral JAK inhibitors in the Field of AD, a number of localJAK inhibitors have also made progress.
January 2020, delgocitnib (JTE-052) cream was approved by the Japan Medicines and Medical Devices Administration (PMDA) for use in light and moderate AD adult patients;
.